Its about time
Medmira receives $100,000 Multiplo order in Uzbekistan 2015-01-28 08:42 ET - News Release Ms. Andrea Young reports TWO OF MEDMIRA'S MULTIPLO TESTS PROCURED FOR UNAIDS PROGRAM IN CENTRAL ASIA Medmira Inc. has received payment for an initial $100,000 order of its Multiplo rapid tests, which will be used in a collaborative mobile health initiative in Uzbekistan. Donated by the Government of the Russian Federation and aligned with UNAIDS and World Health Organization (WHO) global health priorities, these innovative mobile clinics are mini hospitals on wheels that travel to the most remote areas of a country providing cutting edge medical services, which would be otherwise unavailable. The unique, portable, and easy-to-use Multiplo rapid tests will enable Uzbekistan's Republican AIDS Center, the organization operating the mobile clinics, to provide highly accurate, on-the-spot screening and prevention initiatives for HIV, syphilis (TP), hepatitis B (HBc) and C (HCV). "Working with UNAIDS and other collaborators on this important program in Uzbekistan is garnering international recognition for our Multiplo products. We fully support the work of UNAIDS and related organizations, including the WHO, UNICEF and World Bank, and look forward to being a part of their screening and prevention programs in Central Asian countries, such as Uzbekistan," said Hermes Chan, CEO, MedMira Inc. "MedMira's rapid tests, built on our innovative RVF technology platform, have a role to play in screening programs, regardless of whether the testing is performed in a state-of-the-art hospital lab or the back of a mobile clinic vehicle in the field. No other technology can match the speed, ease of use, and the versatility of Multiplo tests." UNAIDS unites the efforts of 11 UN organizations - UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO, and the World Bank - and works in conjunction with the Republican AIDS Center, part of the Ministry of Health of the Republic of Uzbekistan, to facilitate innovative screening programs that localize global health strategies and initiatives. MedMira's Multiplo rapid tests, which deliver multiple, instant results, will enable to the Center to simultaneously double or triple its testing and prevention efforts in the mobile clinics. Chan continued "Equipped with Multiplo tests, the mobile clinics in Uzbekistan can increase screening efforts to prevent the spread of not just a single disease but now HIV, syphilis, hepatitis B and C at the same time. As healthcare providers, aid organizations, and public health agencies around the world implement our unique products, they immediately realize the value and benefits that are brought to their programs. These benefits include fewer patients lost to follow-up and being able to provide immediate counselling and treatment because of the speed of the tests; as well as maximizing resource utilization and improving the bottom line by delivering multiple results on a single test." Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests are already being used in testing programs in several Latin America countries and in programs in India. Additionally, the Multiplo TP/HIV test is in the final technical evaluation phase of the WHO Prequalification of Diagnostics program and MedMira is conducting multi-center clinical trials to support United States FDA approval for the Multiplo HBc/HIV/HCV test, where it will be used by customers in military, public health, tissue banking, and mainstream healthcare sectors. We seek Safe Harbor. © 2015 Canjex Publishing Ltd. All rights reserved. Mobile Old Site Home Daily Products Help Contact Us Your Account System Status © 2015 Medmira receives $100,000 Multiplo order in Uzbekistan 2015-01-28 08:42 ET - News Release Ms. Andrea Young reports TWO OF MEDMIRA'S MULTIPLO TESTS PROCURED FOR UNAIDS PROGRAM IN CENTRAL ASIA Medmira Inc. has received payment for an initial $100,000 order of its Multiplo rapid tests, which will be used in a collaborative mobile health initiative in Uzbekistan. Donated by the Government of the Russian Federation and aligned with UNAIDS and World Health Organization (WHO) global health priorities, these innovative mobile clinics are mini hospitals on wheels that travel to the most remote areas of a country providing cutting edge medical services, which would be otherwise unavailable. The unique, portable, and easy-to-use Multiplo rapid tests will enable Uzbekistan's Republican AIDS Center, the organization operating the mobile clinics, to provide highly accurate, on-the-spot screening and prevention initiatives for HIV, syphilis (TP), hepatitis B (HBc) and C (HCV). "Working with UNAIDS and other collaborators on this important program in Uzbekistan is garnering international recognition for our Multiplo products. We fully support the work of UNAIDS and related organizations, including the WHO, UNICEF and World Bank, and look forward to being a part of their screening and prevention programs in Central Asian countries, such as Uzbekistan," said Hermes Chan, CEO, MedMira Inc. "MedMira's rapid tests, built on our innovative RVF technology platform, have a role to play in screening programs, regardless of whether the testing is performed in a state-of-the-art hospital lab or the back of a mobile clinic vehicle in the field. No other technology can match the speed, ease of use, and the versatility of Multiplo tests." UNAIDS unites the efforts of 11 UN organizations - UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO, and the World Bank - and works in conjunction with the Republican AIDS Center, part of the Ministry of Health of the Republic of Uzbekistan, to facilitate innovative screening programs that localize global health strategies and initiatives. MedMira's Multiplo rapid tests, which deliver multiple, instant results, will enable to the Center to simultaneously double or triple its testing and prevention efforts in the mobile clinics. Chan continued "Equipped with Multiplo tests, the mobile clinics in Uzbekistan can increase screening efforts to prevent the spread of not just a single disease but now HIV, syphilis, hepatitis B and C at the same time. As healthcare providers, aid organizations, and public health agencies around the world implement our unique products, they immediately realize the value and benefits that are brought to their programs. These benefits include fewer patients lost to follow-up and being able to provide immediate counselling and treatment because of the speed of the tests; as well as maximizing resource utilization and improving the bottom line by delivering multiple results on a single test." Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests are already being used in testing programs in several Latin America countries and in programs in India. Additionally, the Multiplo TP/HIV test is in the final technical evaluation phase of the WHO Prequalification of Diagnostics program and MedMira is conducting multi-center clinical trials to support United States FDA approval for the Multiplo HBc/HIV/HCV test, where it will be used by customers in military, public health, tissue banking, and mainstream healthcare sectors. We seek Safe Harbor. © 2015 Canjex Publishing Ltd. All rights reserved. Mobile Old Site Home Daily Products Help Contact Us Your Account System Status © 2015 Medmira receives $100,000 Multiplo order in Uzbekistan 2015-01-28 08:42 ET - News Release Ms. Andrea Young reports TWO OF MEDMIRA'S MULTIPLO TESTS PROCURED FOR UNAIDS PROGRAM IN CENTRAL ASIA Medmira Inc. has received payment for an initial $100,000 order of its Multiplo rapid tests, which will be used in a collaborative mobile health initiative in Uzbekistan. Donated by the Government of the Russian Federation and aligned with UNAIDS and World Health Organization (WHO) global health priorities, these innovative mobile clinics are mini hospitals on wheels that travel to the most remote areas of a country providing cutting edge medical services, which would be otherwise unavailable. The unique, portable, and easy-to-use Multiplo rapid tests will enable Uzbekistan's Republican AIDS Center, the organization operating the mobile clinics, to provide highly accurate, on-the-spot screening and prevention initiatives for HIV, syphilis (TP), hepatitis B (HBc) and C (HCV). "Working with UNAIDS and other collaborators on this important program in Uzbekistan is garnering international recognition for our Multiplo products. We fully support the work of UNAIDS and related organizations, including the WHO, UNICEF and World Bank, and look forward to being a part of their screening and prevention programs in Central Asian countries, such as Uzbekistan," said Hermes Chan, CEO, MedMira Inc. "MedMira's rapid tests, built on our innovative RVF technology platform, have a role to play in screening programs, regardless of whether the testing is performed in a state-of-the-art hospital lab or the back of a mobile clinic vehicle in the field. No other technology can match the speed, ease of use, and the versatility of Multiplo tests." UNAIDS unites the efforts of 11 UN organizations - UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO, and the World Bank - and works in conjunction with the Republican AIDS Center, part of the Ministry of Health of the Republic of Uzbekistan, to facilitate innovative screening programs that localize global health strategies and initiatives. MedMira's Multiplo rapid tests, which deliver multiple, instant results, will enable to the Center to simultaneously double or triple its testing and prevention efforts in the mobile clinics. Chan continued "Equipped with Multiplo tests, the mobile clinics in Uzbekistan can increase screening efforts to prevent the spread of not just a single disease but now HIV, syphilis, hepatitis B and C at the same time. As healthcare providers, aid organizations, and public health agencies around the world implement our unique products, they immediately realize the value and benefits that are brought to their programs. These benefits include fewer patients lost to follow-up and being able to provide immediate counselling and treatment because of the speed of the tests; as well as maximizing resource utilization and improving the bottom line by delivering multiple results on a single test." Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests are already being used in testing programs in several Latin America countries and in programs in India. Additionally, the Multiplo TP/HIV test is in the final technical evaluation phase of the WHO Prequalification of Diagnostics program and MedMira is conducting multi-center clinical trials to support United States FDA approval for the Multiplo HBc/HIV/HCV test, where it will be used by customers in military, public health, tissue banking, and mainstream healthcare sectors. We seek Safe Harbor. © 2015 Canjex Publishing Ltd. All rights reserved. Mobile Old Site Home Daily Products Help Contact Us Your Account System Status © 2015